
CLAIMS


1. A compound of formula (II)



(II)

or a pharmaceutically acceptable salt and/or solvate thereof;

wherein

- Y^1 is a 9- or 10-membered bicyclic heteroaryl selected from the following formulae





wherein

$\mathbf{A^1}$, $\mathbf{A^2}$, $\mathbf{A^3}$, $\mathbf{A^4}$, $\mathbf{A^5}$, $\mathbf{A^6}$ and $\mathbf{A^7}$ are each independently selected from C-$\mathbf{R^7}$ and N;

$\mathbf{A^8}$, $\mathbf{A^9}$, $\mathbf{A^{10}}$ and $\mathbf{A^{11}}$ are each independently selected from C-$\mathbf{R^7}$ and N, provided that at least one of $\mathbf{A^8}$, $\mathbf{A^9}$, $\mathbf{A^{10}}$ or $\mathbf{A^{11}}$ is N;

$\mathbf{G^1}$ is selected from C-$\mathbf{R^3}$ and N;

$\mathbf{G^2}$ is selected from O and N-$\mathbf{R^4}$;

B is selected from O, S and N-$\mathbf{R^5}$,
provided that when $\mathbf{A^5}$, $\mathbf{A^6}$ and $\mathbf{A^7}$ are C-$\mathbf{R^7}$, then **B** is not S; and

$\mathbf{R^2}$ is selected from hydrogen, halogen, cyano, amino, hydroxy, -(C_1-C_6) alkyl, -(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl, heteroaryl, -(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) heterocycloalkyl, -O$\mathbf{R^{15}}$, -(C_1-C_6) alkylene-O$\mathbf{R^{15}}$, -O-(C_2-C_6) alkylene-O$\mathbf{R^{15}}$, -N$\mathbf{R^{16}}$(C_2-C_6) alkylene-O$\mathbf{R^{15}}$, -N$\mathbf{R^{17}R^{18}}$, -(C_1-C_6) alkylene-N$\mathbf{R^{17}R^{18}}$, -O-(C_2-C_6) alkylene-N$\mathbf{R^{17}R^{18}}$, -N$\mathbf{R^{16}}$-(C_2-C_6) alkylene-N$\mathbf{R^{17}R^{18}}$, -(C_1-C_6) alkylene-SO_2-N$\mathbf{R^{17}R^{18}}$, -NR^{16}-SO_2-$\mathbf{R^{15}}$, -(C_1-C_6) alkylene-N$\mathbf{R^{16}}$-SO_2-$\mathbf{R^{15}}$, -O-(C_2-C_6) alkylene-N$\mathbf{R^{16}}$-SO_2-$\mathbf{R^{15}}$,

-N**R**^{16}-(C_2-C_6) alkylene-N**R**^{17}-SO_2-**R**^{15}, -C(O)-N**R**^{17}**R**^{18}, -(C_1-C_6) alkylene-C(O)-N**R**^{17}**R**^{18}, -O-(C_1-C_6) alkylene-C(O)-N**R**^{17}**R**^{18}, -N**R**^{16}-(C_1-C_6) alkylene-C(O)-N**R**^{17}**R**^{18}, -N**R**^{16}C(O)-**R**^{15}, -(C_1-C_6) alkylene-N**R**^{16}C(O)-**R**^{15}, -O-(C_2-C_6) alkylene-N**R**^{16}C(O)-**R**^{15}, -N**R**^{16}-(C_2-C_6) alkylene-N**R**^{16}C(O)-**R**^{15}, -C(O)-**R**^{15}, -C(O)O**R**^{15}, -(C_1-C_6) alkylene-C(O)O**R**^{15}, -O-(C_1-C_6) alkylene-C(O)O**R**^{15}, and -N**R**^{16}-(C_1-C_6) alkylene-C(O)O**R**^{15};

R^3 is selected from hydrogen, halogen, cyano, amino, hydroxy, -(C_1-C_6) alkyl, -(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl, heteroaryl, -(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) heterocycloalkyl, -O**R**^{15}, -(C_1-C_6) alkylene-O**R**^{15}, -O-(C_2-C_6) alkylene-O**R**^{15}, -N**R**^{16}(C_2-C_6) alkylene-O**R**^{15}, -N**R**^{17}**R**^{18}, -(C_1-C_6) alkylene-N**R**^{17}**R**^{18}, -O-(C_2-C_6) alkylene-N**R**^{17}**R**^{18}, -N**R**^{16}-(C_2-C_6) alkylene-N**R**^{17}**R**^{18}, -(C_1-C_6) alkylene-SO_2-N**R**^{17}**R**^{18}, -NR^{16}-SO_2-**R**^{15}, -(C_1-C_6) alkylene-N**R**^{16}-SO_2-**R**^{15}, -O-(C_2-C_6) alkylene-N**R**^{16}-SO_2-**R**^{15}, -N**R**^{16}-(C_2-C_6) alkylene-N**R**^{17}-SO_2-**R**^{15}, -C(O)-N**R**^{17}**R**^{18}, -(C_1-C_6) alkylene-C(O)-N**R**^{17}**R**^{18}, -O-(C_1-C_6) alkylene-C(O)-N**R**^{17}**R**^{18}, -N**R**^{16}-(C_1-C_6) alkylene-C(O)-N**R**^{17}**R**^{18}, -N**R**^{16}C(O)-**R**^{15}, -(C_1-C_6) alkylene-N**R**^{16}C(O)-**R**^{15}, -O-(C_2-C_6) alkylene-N**R**^{16}C(O)-**R**^{15}, -N**R**^{16}-(C_2-C_6) alkylene-N**R**^{16}C(O)-**R**^{15}, -C(O)-**R**^{15}, -C(O)O**R**^{15}, -(C_1-C_6) alkylene-C(O)O**R**^{15}, -O-(C_1-C_6) alkylene-C(O)O**R**^{15}, and -N**R**^{16}-(C_1-C_6) alkylene-C(O)O**R**^{15};

R^4 is selected from hydrogen, -(C_1-C_6) alkyl, -(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) heterocycloalkyl, -(C_1-C_6) alkylene-aryl, -(C_1-C_6) alkylene-heteroaryl, -(C_1-C_6) alkylene-O**R**^{15}, -(C_1-C_6) alkylene-N**R**^{17}**R**^{18}, -(C_1-C_6) alkylene-C(O)-N**R**^{17}**R**^{18}, -(C_1-C_6) alkylene-N**R**^{16}C(O)-**R**^{15}, -(C_1-C_6) alkylene-C(O)O**R**^{15}, and -(C_1-C_6) alkylene-OC(O)-**R**^{15};

R^5 is selected from hydrogen, -(C_1-C_6) alkyl, -(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl, heteroaryl, -(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) heterocycloalkyl, -(C_1-C_6) alkylene-aryl, -(C_1-C_6) alkylene-heteroaryl, -(C_1-C_6) alkylene-O**R**^{15}, -(C_1-C_6) alkylene-N**R**^{17}**R**^{18}, -(C_1-C_6) alkylene-C(O)-N**R**^{17}**R**^{18}, -(C_1-C_6) alkylene-N**R**^{16}C(O)-**R**^{15}, -(C_1-C_6) alkylene-C(O)O**R**^{15}, and -(C_1-C_6) alkylene-OC(O)-**R**^{15};

$\mathbf{R^7}$ is selected from hydrogen, halogen, amino, hydroxy, -(C_1-C_6) alkyl, -(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) heterocycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl, heteroaryl, -O$\mathbf{R^{15}}$, -(C_1-C_6) alkylene-O$\mathbf{R^{15}}$, -O-(C_2-C_6) alkylene-O$\mathbf{R^{15}}$, -N$\mathbf{R^{16}}$(C_2-C_6) alkylene-O$\mathbf{R^{15}}$, -N$\mathbf{R^{17}R^{18}}$, -(C_1-C_6) alkylene-N$\mathbf{R^{17}R^{18}}$, -O-(C_2-C_6) alkylene-N$\mathbf{R^{17}R^{18}}$, -N$\mathbf{R^{16}}$-(C_2-C_6) alkylene-N$\mathbf{R^{17}R^{18}}$, -SO-$\mathbf{R^{15}}$, -SO_2-$\mathbf{R^{15}}$, -SO_2N$\mathbf{R^{17}R^{18}}$, -(C_1-C_6) alkylene-SO_2-N$\mathbf{R^{17}R^{18}}$, -N$\mathbf{R^{16}}$-SO_2-$\mathbf{R^{15}}$, -(C_1-C_6) alkylene-N$\mathbf{R^{16}}$-SO_2-$\mathbf{R^{15}}$, -O-(C_2-C_6) alkylene-N$\mathbf{R^{16}}$-SO_2-$\mathbf{R^{15}}$, -N$\mathbf{R^{16}}$-(C_2-C_6) alkylene-N$\mathbf{R^{17}}$-SO_2-$\mathbf{R^{15}}$, -C(O)-N$\mathbf{R^{17}R^{18}}$, -(C_1-C_6) alkylene-C(O)-N$\mathbf{R^{17}R^{18}}$, -O-(C_1-C_6) alkylene-C(O)-N$\mathbf{R^{17}R^{18}}$, -N$\mathbf{R^{16}}$-(C_1-C_6) alkylene-C(O)-N$\mathbf{R^{17}R^{18}}$, -N$\mathbf{R^{16}}$C(O)-$\mathbf{R^{15}}$, -(C_1-C_6) alkylene-N$\mathbf{R^{16}}$C(O)-$\mathbf{R^{15}}$, -O-(C_2-C_6) alkylene-N$\mathbf{R^{16}}$C(O)-$\mathbf{R^{15}}$, -N$\mathbf{R^{16}}$-(C_2-C_6) alkylene-N$\mathbf{R^{17}}$C(O)-$\mathbf{R^{15}}$, -C(O)-$\mathbf{R^{15}}$, -C(O)-O$\mathbf{R^{15}}$, -(C_1-C_6) alkylene-C(O)-O$\mathbf{R^{15}}$, -O-(C_1-C_6) alkylene-C(O)-O$\mathbf{R^{15}}$, -N$\mathbf{R^{16}}$-(C_1-C_6) alkylene-C(O)-O$\mathbf{R^{15}}$, -OC(O)-$\mathbf{R^{15}}$, -(C_1-C_6) alkylene-OC(O)-$\mathbf{R^{15}}$, -O-(C_2-C_6) alkylene-OC(O)-$\mathbf{R^{15}}$, -N$\mathbf{R^{16}}$-(C_2-C_6) alkylene-OC(O)-$\mathbf{R^{15}}$, and -N$\mathbf{R^{16}}$-C(O)-O$\mathbf{R^{15}}$;

wherein

each of said -(C_1-C_6) alkyl or -(C_1-C_6) alkylene in $\mathbf{R^2}$, $\mathbf{R^3}$, $\mathbf{R^4}$, $\mathbf{R^5}$ or $\mathbf{R^7}$ is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino, -O-(C_1-C_6) alkyl, -NH-(C_1-C_6) alkyl, and -N-((C_1-C_6) alkyl)$_2$;

each of said -(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl or heteroaryl in $\mathbf{R^2}$, $\mathbf{R^3}$, $\mathbf{R^4}$, $\mathbf{R^5}$ or $\mathbf{R^7}$ is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino, -(C_1-C_6) alkyl, -CH_2-O-(C_1-C_6) alkyl, -CH_2-NH-(C_1-C_6) alkyl, -CH_2-N-((C_1-C_6) alkyl)$_2$, -O-(C_1-C_6) alkyl, -NH-(C_1-C_6) alkyl, and -N-((C_1-C_6) alkyl)$_2$;

$\mathbf{R^{15}}$, $\mathbf{R^{16}}$, $\mathbf{R^{17}}$ and $\mathbf{R^{18}}$ are each independently selected from hydrogen, -(C_1-C_6) haloalkyl, -(C_1-C_6) alkyl, -(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl, heteroaryl, -(C_1-C_6) alkylene-(C_3-C_7) heterocycloalkyl, -(C_1-C_6) alkylene-heteroaryl, and


-(C_1-C_6) alkylene-aryl; and/or two groups selected from **R^{15}**, **R^{16}**, **R^{17}** and **R^{18}** form together a cycle selected from -(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl, and heteroaryl;


wherein

each of said -(C_1-C_6) alkyl or -(C_1-C_6) alkylene in **R^{15}**, **R^{16}**, **R^{17}** or **R^{18}** is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino, -O-(C_1-C_6) alkyl, -NH-(C_1-C_6) alkyl and -N-((C_1-C_6) alkyl)$_2$;

each of said -(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl or heteroaryl in **R^{15}**, **R^{16}**, **R^{17}** or **R^{18}** is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, amino, -(C_1-C_6) alkyl, -CH_2-O-(C_1-C_6) alkyl, -CH_2-NH-(C_1-C_6) alkyl, -CH_2-N-((C_1-C_6) alkyl)$_2$, -O-(C_1-C_6) alkyl, -NH-(C_1-C_6) alkyl and -N-((C_1-C_6) alkyl)$_2$;

- Y^2 is a 5- or 6-membered heteroaryl or 6-membered aryl selected from the following formulae





wherein **R**^{12}, **R**^{13}, **R**^{14} and **R**$^{25'}$ are each independently selected from hydrogen, halogen, cyano, hydroxy, amino, -(C_1-C_6) alkyl, -(C_3-C_6) cycloalkyl, -CH_2-O-(C_1-C_6) alkyl, -O-(C_1-C_6) alkyl, and -N-((C_1-C_6) alkyl)$_2$;

wherein each of said -(C_1-C_6) alkyl in **R**^{12}, **R**^{13}, **R**^{14} or **R**$^{25'}$ is optionally substituted with at least one group selected from halogen, cyano, hydroxy, amino, -O-(C_1-C_6) alkyl, and -N-((C_1-C_6) alkyl)$_2$;

- **L** is -(C**R**^{10}**R**^{11})$_n$;

wherein

n is an integer selected from 0, 1, 2, 3 and 4;

R^{10} and **R**^{11} are independently selected from hydrogen, halogen, hydroxy, amino, -(C_1-C_3) alkyl, -(C_1-C_2) haloalkyl, -(C_1-C_2) hydroxyalkyl, -(C_1-C_2) aminoalkyl, -O-(C_1-C_4) alkyl, -NH-(C_1-C_3) alkyl, and -N-((C_1-C_3) alkyl)$_2$;

or **R**^{10} and **R**^{11} form together with the carbon atom to which they are bond a (C_3-C_6) cycloalkyl;

- **Z**$^{1'}$ is a -(C_3-C_7) heterocycloalkyl comprising at least one nitrogen atom;

wherein

each nitrogen atom of said (C_3-C_7) heterocycloalkyl in $\mathbf{Z^{1'}}$ is optionally substituted with at least one group selected from -(C_1-C_6) alkyl, -(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl, heteroaryl, -(C_1-C_6) alkylene-O-(C_1-C_6) alkyl, -(C_1-C_6) alkylene-(C_3-C_7) heterocycloalkyl, -(C_1-C_6) alkylene-aryl, -(C_1-C_6) alkylene-heteroaryl, and -(C_1-C_6) alkylene-O-(C_3-C_7) cycloalkyl;

each carbon atom of said (C_3-C_7) heterocycloalkyl in $\mathbf{Z^{1'}}$ is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, -(C_1-C_6) alkyl, -(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl, heteroaryl, -(C_1-C_6) alkylene-O-(C_1-C_6) alkyl, -(C_1-C_6) alkylene-O-(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) heterocycloalkyl, -(C_1-C_6) alkylene-aryl, -(C_1-C_6) alkylene-heteroaryl, -O-(C_1-C_6) alkyl, and -O-(C_3-C_7) cycloalkyl; and

wherein each of said -(C_1-C_6) alkyl, -(C_1-C_6) alkylene -(C_3-C_7) cycloalkyl or -(C_3-C_7) heterocycloalkyl in $\mathbf{Z^{1'}}$ is optionally substituted with at least one halogen; and

wherein each of said aryl or heteroaryl in $\mathbf{Z^{1'}}$ is optionally substituted with at least one group selected from halogen, CN, -(C_1-C_6) alkyl, -O-(C_1-C_6) alkyl, and O-(C_3-C_7) cycloalkyl; provided that the compound is not selected from:


1-(5-(pyrrolidin-3-yl)thiophen-2-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one; and

2-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)-1-(5-(pyrrolidin-3-yl)thiophen-2-yl)ethan-1-one;

or a pharmaceutically acceptable salt and/or solvate of any one thereof.

2. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim **1**, wherein $\mathbf{Y^1}$ is a 9- or 10-membered bicyclic heteroaryl selected from:

the following formulae



wherein $\mathbf{A^1}$-$\mathbf{A^4}$, $\mathbf{A^6}$, $\mathbf{A^7}$, **B**, $\mathbf{G^1}$ and $\mathbf{R^2}$ are independently as defined in claim **1**; and


the following formula




wherein $\mathbf{A^8}$-$\mathbf{A^{11}}$ and $\mathbf{G^2}$ are independently as defined in claim **1**.

3. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim **1**, wherein $\mathbf{Y^1}$ is selected from:

(i) a 10-membered bicyclic [6,6] heteroaryl selected from the following formulae




and the following formulae




wherein **R²**, **R³** and **R⁷** are independently as defined in claim **1**;

(ii) a 9-membered bicyclic [6,5] heteroaryl selected from


the following formulae




the following formulae




the following formulae




the following formulae






and the following formulae



wherein **R²**, **R³**, **R⁵** and **R⁷** are independently as defined in claim **1**;


and the following formula




wherein **R²**, **R³** and **R⁷** are independently as defined in claim **1**; and

(iii) a 9-membered bicyclic [5,6] heteroaryl selected from:

the following formulae




and the following formulae



wherein $\mathbf{A^1}$, $\mathbf{A^3}$, $\mathbf{A^3}$, $\mathbf{A^4}$, $\mathbf{R^2}$, $\mathbf{R^4}$ and $\mathbf{R^7}$ are independently as defined in claim **1**.


4. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims **1** to **3**, wherein $\mathbf{Y^1}$ is selected from:

(i) a 10-membered bicyclic [6,6] heteroaryl selected from the following formulae




wherein $\mathbf{R^2}$, $\mathbf{R^3}$ and $\mathbf{R^7}$ are independently as defined in claim **1**;

(ii) a 9-membered bicyclic [6,5] heteroaryl selected from the following formulae



wherein R^2, R^3, R^5 and R^7 are independently as defined in claim **1**;


(iii) a 9-membered bicyclic [5,6] heteroaryl selected from the following formulae



wherein R^2, R^5 and R^7 are independently as defined in claim **1**.

5. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims **1** to **4**, wherein Y^1 is 6-methoxy-2-methylquinazolin-4-yl.

6. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims **1** to **5**, wherein Y^2 is selected from the following formulae:




wherein R^{12}, R^{13} and R^{14} are each independently as defined in claim **1**.

7. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim **6**, wherein $\mathbf{R^{12}}$, $\mathbf{R^{13}}$, and $\mathbf{R^{14}}$ are each independently hydrogen.

8. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims **1** to **7**, wherein **n** is 0.

9. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims **1** to **8**, wherein $\mathbf{Z^{1'}}$ is a -(C_3-C_7) heterocycloalkyl selected from the following formulae



wherein


$\mathbf{R^{21'}}$ is selected from hydrogen, -(C_1-C_6) alkyl, -(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl, heteroaryl, -(C_1-C_6) alkylene-O-(C_1-C_6) alkyl, -(C_1-C_6) alkylene-(C_3-C_7) heterocycloalkyl, -(C_1-C_6) alkylene-aryl, -(C_1-C_6) alkylene-heteroaryl, and -(C_1-C_6) alkylene-O-(C_3-C_7) cycloalkyl; and

$\mathbf{R^{22'}}$ is selected from hydrogen, halogen, cyano, hydroxy, oxo, -(C_1-C_6) alkyl, -(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl, heteroaryl, -(C_1-C_6) alkylene-O-(C_1-C_6) alkyl, -(C_1-C_6) alkylene-O-(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) heterocycloalkyl, -(C_1-C_6) alkylene-aryl, -(C_1-C_6) alkylene-heteroaryl, -O-(C_1-C_6) alkyl, and -O-(C_3-C_7) cycloalkyl;

wherein each of said -(C_1-C_6) alkyl, -(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl or -(C_3-C_7) heterocycloalkyl in $\mathbf{R^{21'}}$ or $\mathbf{R^{22'}}$ is optionally substituted with at least one halogen; and

wherein each of said aryl or heteroaryl in $\mathbf{R^{21'}}$ or $\mathbf{R^{22'}}$ is optionally substituted with at least one group selected from halogen, CN, -(C_1-C_6) alkyl, -O-(C_1-C_6) alkyl, and -O-(C_3-C_7) cycloalkyl.

10. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims **1** to **8**, wherein $\mathbf{Z^{1'}}$ is a -(C_3-C_7) heterocycloalkyl of the following formula



wherein


$\mathbf{R^{21'}}$ is selected from hydrogen, -(C_1-C_6) alkyl, -(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl, heteroaryl, -(C_1-C_6) alkylene-O-(C_1-C_6) alkyl, -(C_1-C_6) alkylene-(C_3-C_7) heterocycloalkyl, -(C_1-C_6) alkylene-aryl, -(C_1-C_6) alkylene-heteroaryl, and -(C_1-C_6) alkylene-O-(C_3-C_7) cycloalkyl; and

$\mathbf{R^{22'}}$ is selected from hydrogen, halogen, cyano, hydroxy, oxo, -(C_1-C_6) alkyl, -(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl, heteroaryl, -(C_1-C_6) alkylene-O-(C_1-C_6) alkyl, -(C_1-C_6) alkylene-O-(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) heterocycloalkyl, -(C_1-C_6) alkylene-aryl, -(C_1-C_6) alkylene-heteroaryl, -O-(C_1-C_6) alkyl and -O-(C_3-C_7) cycloalkyl;

wherein each of said -(C_1-C_6) alkyl, -(C_1-C_6) alkylene -(C_3-C_7) cycloalkyl or -(C_3-C_7) heterocycloalkyl in $\mathbf{R^{21'}}$ is optionally substituted with at least one halogen; and

wherein each of said aryl or heteroaryl in **R$^{21'}$** is optionally substituted with at least one group selected from halogen, CN, -(C_1-C_6) alkyl, -O-(C_1-C_6) alkyl and O-(C_3-C_7) cycloalkyl.

11. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims **1** to **8**, wherein **Z$^{1'}$** is a -(C_3-C_7) heterocycloalkyl of the following formula



wherein

R$^{21'}$ is selected from hydrogen, -(C_1-C_6) alkyl, -(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl, heteroaryl, -(C_1-C_6) alkylene-O-(C_1-C_6) alkyl, -(C_1-C_6) alkylene-(C_3-C_7) heterocycloalkyl, -(C_1-C_6) alkylene-aryl, -(C_1-C_6) alkylene-heteroaryl, and -(C_1-C_6) alkylene-O-(C_3-C_7) cycloalkyl; and

R$^{22'}$ is selected from hydrogen, halogen, cyano, hydroxy, oxo, -(C_1-C_6) alkyl, -(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl, heteroaryl, -(C_1-C_6) alkylene-O-(C_1-C_6) alkyl, -(C_1-C_6) alkylene-O-(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) heterocycloalkyl, -(C_1-C_6) alkylene-aryl, -(C_1-C_6) alkylene-heteroaryl, -O-(C_1-C_6) alkyl and -O-(C_3-C_7) cycloalkyl;

wherein each of said -(C_1-C_6) alkyl, -(C_1-C_6) alkylene -(C_3-C_7) cycloalkyl or -(C_3-C_7) heterocycloalkyl in $\mathbf{R^{21'}}$ is optionally substituted with at least one halogen; and

wherein each of said aryl or heteroaryl in $\mathbf{R^{21'}}$ is optionally substituted with at least one group selected from halogen, CN, -(C_1-C_6) alkyl, -O-(C_1-C_6) alkyl and O-(C_3-C_7) cycloalkyl.

12. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims **9** to **11**, wherein:

$\mathbf{R^{21'}}$ is selected from hydrogen, -(C_1-C_3) alkyl, -(C_3-C_5) cycloalkyl, -(C_1-C_3) alkylene-(C_3-C_5) cycloalkyl, oxetanyl, and -(C_1-C_3) alkylene-O-(C_1-C_3) alkyl; and

$\mathbf{R^{22'}}$ is selected from hydrogen, fluoro, trifluoromethyl, cyano, hydroxy and -O-(C_1-C_3) alkyl.

13. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims **1** to **8**, wherein $\mathbf{Z^{1'}}$ is selected from azetidin-3-yl, 1-methylazetidin-3-yl, 3-fluoroazetidin-3-yl, 3-hydroxyazetidin-3-yl, 3-methoxyazetidin-3-yl, 1-methylpiperidin-4-yl, 1-(2-methoxyethyl)azetidin-3-yl, pyrrolidin-3-yl, 3-fluoropyrrolidin-3-yl, 3-hydroxypyrrolidin-3-yl, 3-methoxypyrrolidin-3-yl, morpholinomethyl, 3-methoxy-1-methylpyrrolidin-3-yl, piperidin-4-yl, 4-hydroxypiperidin-4-yl, 4-cyano-1-methylpiperidin-4-yl, 3-hydroxy-1-methylpyrrolidin-3-yl, 4-methoxypiperidin-4-yl, 4-hydroxy-1-isopropylpiperidin-4-yl, 1-hydroxy-2-(methylamino)ethyl, 1-(2-fluoroethyl)-4-hydroxypiperidin-4-yl, 4-hydroxy-1-methylpiperidin-4-yl, 4-hydroxy-1,3-dimethylpiperidin-4-yl, 1-(cyclopropylmethyl)-4-hydroxypiperidin-4-yl, 4-hydroxy-1-(2-methoxyethyl)piperidin-4-yl, 1-cyclobutyl-4-hydroxypiperidin-4-yl)thiophen-2-yl, 1-cyclopropyl-4-hydroxypiperidin-4-yl, piperazin-1-yl, 3-hydroxy-1-methylpiperidin-4-yl, 4-hydroxy-1-(oxetan-3-yl)piperidin-4-yl, 4-methoxy-1-methylpiperidin-4-yl, 3-hydroxy-1-methylpiperidin-3-yl, morpholin-4-yl, morpholin-2-yl, 4-methylmorpholin-2-yl, 4-methylmorpholin-3-yl, morpholin-3-

yl, 2-aminoethyl, aminomethyl, and N-(methylamino)-methyl, 3-hydroxy-1-methylazetidin-3-yl, 5-(hydroxy(1-methylpiperidin-4-yl)methyl, 3-hydroxy-1-isopropylazetidin-3-yl, 6-oxa-3-azabicyclo[3.2.1]octan-5-yl, 3-methyl-6-oxa-3-azabicyclo[3.2.1]octan-5-yl, 3-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl, 2-oxa-5-azabicyclo[2.2.1]heptan-1-yl, 5-methyl-2-oxa-5-azabicyclo[2.2.1]heptan-1-yl, 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl, 6,6-difluoro-1,4-oxazepan-2-yl, 2-methylmorpholin-2-yl, 2-(trifluoromethyl)morpholin-2-yl, 2,5-diazabicyclo[2.2.1]heptan-2-yl, 5-isopropyl-2,5-diazabicyclo[2.2.1]heptan-2-yl, 7-hydroxy-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl, 5-hydroxy-2-methyl-2-azabicyclo[2.2.1]heptan-5-yl, 3-hydroxyquinuclidin-3-yl, 5-hydroxy-2-azabicyclo[2.2.1]heptan-5-yl, 1-hydroxy-2-morpholinoethyl, 5-(hydroxy(4-methylmorpholin-2-yl)methyl, 5-(hydroxy(tetrahydro-1H-pyrrolizin-7a(5H)-yl)methyl, and 2-(dimethylamino)-1-hydroxyethyl

.

14. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim **1**, wherein said compound is selected from

2	1-(5-(piperidin-4-yl)thiophen-2-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
3	1-(5-(morpholinomethyl)thiophen-2-yl)-2-((2-(trifluoromethyl)pyrido[2,3-d]pyrimidin-4-yl)thio)ethan-1-one;
4	1-(5-(pyrrolidin-3-yl)thiophen-2-yl)-2-((5-(trifluoromethyl)oxazolo[5,4-b]pyridin-2-yl)thio)ethan-1-one
6	2-((6-methoxy-2-(trifluoromethyl)quinazolin-4-yl)thio)-1-(5-(pyrrolidin-3-yl)thiophen-2-yl)ethan-1-one;
7 and **8**	*(R)*-1-(5-(pyrrolidin-3-yl)thiophen-2-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
	(S)-1-(5-(pyrrolidin-3-yl)thiophen-2-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
9	1-(1-(pyrrolidin-3-yl)-1H-pyrazol-4-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
10	1-(5-(azetidin-3-yl)thiophen-2-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
11	1-(5-(1-methylazetidin-3-yl)thiophen-2-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;

12	1-(5-(1-(2-methoxyethyl)azetidin-3-yl)thiophen-2-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
13	1-(5-(3-methoxyazetidin-3-yl)thiophen-2-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
14	1-(5-(3-hydroxyazetidin-3-yl)thiophen-2-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one
15	1-(6-(piperazin-1-yl)pyridin-3-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
16	1-(6-(3-hydroxypyrrolidin-3-yl)pyridin-3-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
17	1-(2-(pyrrolidin-3-yl)thiazol-5-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
18	1-(5-(3-hydroxypyrrolidin-3-yl)thiophen-2-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
19	1-(4-(pyrrolidin-3-yl)thiophen-2-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
21	2-((2-(difluoromethyl)-6-methoxypyrido[2,3-d]pyrimidin-4-yl)thio)-1-(6-morpholinopyridin-3-yl)ethan-1-one;
22	1-(6-(3-methoxypyrrolidin-3-yl)pyridin-3-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
23	1-(6-(3-fluoropyrrolidin-3-yl)pyridin-3-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
24	1-(6-(3-fluoropyrrolidin-3-yl)pyridin-3-yl)-2-((1-(2-methoxyethyl)-6-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)ethan-1-one;
25	1-(6-(3-fluoropyrrolidin-3-yl)pyridin-3-yl)-2-((1-methyl-6-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)ethan-1-one;
26	1-(5-(4-hydroxypiperidin-4-yl)thiophen-2-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
27	2-((2-(difluoromethyl)-6-methoxypyrido[2,3-d]pyrimidin-4-yl)thio)-1-(6-(piperazin-1-yl)pyridin-3-yl)ethan-1-one;
28	1-(5-(3-fluoroazetidin-3-yl)thiophen-2-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
29	1-(5-(3-fluoroazetidin-3-yl)thiophen-2-yl)-2-((1-(2-methoxyethyl)-6-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)ethan-1-one;
30	1-(5-(3-fluoroazetidin-3-yl)thiophen-2-yl)-2-((1-methyl-6-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)ethan-1-one;

31	2-((2-(difluoromethyl)-6-methoxypyrido[2,3-d]pyrimidin-4-yl)thio)-1-(5-(3-fluoroazetidin-3-yl)thiophen-2-yl)ethan-1-one;
32	2-((2-(difluoromethyl)-6-methoxypyrido[2,3-d]pyrimidin-4-yl)thio)-1-(6-(3-fluoropyrrolidin-3-yl)pyridin-3-yl)ethan-1-one;
33	1-(5-(3-fluoroazetidin-3-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
34	1-(5-(3-methoxypyrrolidin-3-yl)thiophen-2-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
35	1-(2-(pyrrolidin-3-yl)pyridin-4-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
36	1-(2-(azetidin-3-yl)thiazol-5-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
37	2-((2-(difluoromethyl)-6-methoxypyrido[2,3-d]pyrimidin-4-yl)thio)-1-(5-(4-hydroxypiperidin-4-yl)thiophen-2-yl)ethan-1-one;
38	2-((2-(difluoromethyl)-6-methoxypyrido[2,3-d]pyrimidin-4-yl)thio)-1-(6-(3-hydroxypyrrolidin-3-yl)pyridin-3-yl)ethan-1-one;
52	1-(5-(3-fluoropyrrolidin-3-yl)thiophen-2-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
53	1-(3-(pyrrolidin-3-yl)isothiazol-5-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
54	2-((2-(difluoromethyl)-6-methoxypyrido[2,3-d]pyrimidin-4-yl)thio)-1-(2-(3-hydroxyazetidin-3-yl)thiazol-5-yl)ethan-1-one;
55	2-((2-(difluoromethyl)-6-methoxypyrido[2,3-d]pyrimidin-4-yl)thio)-1-(4-(3-hydroxypyrrolidin-3-yl)phenyl)ethan-1-one;
56	2-((2-(difluoromethyl)-6-methoxypyrido[2,3-d]pyrimidin-4-yl)thio)-1-(2-(3-fluoroazetidin-3-yl)thiazol-5-yl)ethan-1-one;
57	1-(4-(3-hydroxypyrrolidin-3-yl)phenyl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
58	2-((2-(difluoromethyl)-6-methoxypyrido[2,3-d]pyrimidin-4-yl)thio)-1-(2-(3-hydroxypyrrolidin-3-yl)thiazol-5-yl)ethan-1-one;
59	2-((2-(difluoromethyl)-6-methoxypyrido[2,3-d]pyrimidin-4-yl)thio)-1-(2-(4-hydroxypiperidin-4-yl)thiazol-5-yl)ethan-1-one;
60	2-((7-(difluoromethyl)-1,6-naphthyridin-5-yl)thio)-1-(5-(3-hydroxypyrrolidin-3-yl)thiophen-2-yl)ethan-1-one;
61	2-((2-(difluoromethyl)-6-methoxypyrido[2,3-d]pyrimidin-4-yl)thio)-1-(5-(3-hydroxypyrrolidin-3-yl)thiophen-2-yl)ethan-1-one;
62	1-(5-(4-hydroxypiperidin-4-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
63	2-((7-(difluoromethyl)-1,6-naphthyridin-5-yl)thio)-1-(5-(4-hydroxypiperidin-4-yl)thiophen-2-yl)ethan-1-one;
64	2-((2-(difluoromethyl)-6-methoxypyrido[2,3-d]pyrimidin-4-yl)thio)-1-(2-(3-methoxypyrrolidin-3-yl)thiazol-5-yl)ethan-1-one;

65	2-((2-(difluoromethyl)-6-methoxypyrido[2,3-d]pyrimidin-4-yl)thio)-1-(5-(3-hydroxypyrrolidin-3-yl)pyridin-2-yl)ethan-1-one;
66	2-((2-(difluoromethyl)-6-methoxypyrido[2,3-d]pyrimidin-4-yl)thio)-1-(2-(3-methoxyazetidin-3-yl)thiazol-5-yl)ethan-1-one;
67	2-((2-(difluoromethyl)-6-methoxypyrido[2,3-d]pyrimidin-4-yl)thio)-1-(2-(4-methoxypiperidin-4-yl)thiazol-5-yl)ethan-1-one;
68	2-((2-(difluoromethyl)-6-methoxypyrido[2,3-d]pyrimidin-4-yl)thio)-1-(2-(3-fluoropyrrolidin-3-yl)thiazol-5-yl)ethan-1-one;
69	2-((2-(difluoromethyl)-6-methoxypyrido[2,3-d]pyrimidin-4-yl)thio)-1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)ethan-1-one;
70	1-(5-(3-hydroxypyrrolidin-3-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
71	1-(5-(3-hydroxypyrrolidin-3-yl)thiophen-2-yl)-2-((3-methoxy-7-methyl-1,6-naphthyridin-5-yl)thio)ethan-1-one;
72	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
73	2-((6-chloro-8-fluoro-2-methylquinazolin-4-yl)thio)-1-(5-(4-hydroxypiperidin-4-yl)thiophen-2-yl)ethan-1-one;
74	1-(2-(4-hydroxypiperidin-4-yl)thiazol-5-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
75	1-(2-(4-hydroxy-1-methylpiperidin-4-yl)thiazol-5-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
76	2-((6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-(piperidin-4-yl)thiophen-2-yl)ethan-1-one;
77	2-((6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-(3-methoxypyrrolidin-3-yl)thiophen-2-yl)ethan-1-one;
78	1-(2-(3-hydroxypyrrolidin-3-yl)thiazol-5-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
79	1-(2-(3-hydroxy-1-methylpyrrolidin-3-yl)thiazol-5-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
80	2-((5-fluoro-6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-(4-hydroxypiperidin-4-yl)thiophen-2-yl)ethan-1-one;
81	1-(5-(4-hydroxypiperidin-4-yl)thiophen-2-yl)-2-((2-methyl-6-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
82	2-((6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-(1-methylpiperidin-4-yl)thiophen-2-yl)ethan-1-one;
83	2-((6-ethoxy-2-methylquinazolin-4-yl)thio)-1-(5-(4-hydroxypiperidin-4-yl)thiophen-2-yl)ethan-1-one;
84	2-((6-chloro-7-fluoro-2-methylquinazolin-4-yl)thio)-1-(5-(4-hydroxypiperidin-4-yl)thiophen-2-yl)ethan-1-one;
85	2-((6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-(4-methoxypiperidin-4-yl)thiophen-2-yl)ethan-1-one;
86	1-(5-(3-methoxy-1-methylpyrrolidin-3-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
87	1-(5-(3-hydroxy-1-methylpyrrolidin-3-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;

88	1-(5-(4-methoxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
89	1-(5-(4-hydroxypiperidin-4-yl)thiophen-2-yl)-2-((5-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
90	2-((6-chloro-7-fluoro-2-methylquinazolin-4-yl)thio)-1-(2-(4-hydroxy-1-methylpiperidin-4-yl)thiazol-5-yl)ethan-1-one;
91	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((5-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
92	1-(5-(1-(2-fluoroethyl)-4-hydroxypiperidin-4-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
93	1-(5-(4-hydroxy-1-isopropylpiperidin-4-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
94	1-(5-(4-hydroxy-1-(2-methoxyethyl)piperidin-4-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
95	2-((6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-(morpholin-2-yl)thiophen-2-yl)ethan-1-one;
96	2-((6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-(4-methylmorpholin-2-yl)thiophen-2-yl)ethan-1-one;
97	1-(5-(1-(cyclopropylmethyl)-4-hydroxypiperidin-4-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
98	1-(5-(1-cyclopropyl-4-hydroxypiperidin-4-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
99	1-(5-(1-cyclobutyl-4-hydroxypiperidin-4-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
100	1-(5-(4-hydroxy-1-(oxetan-3-yl)piperidin-4-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
101	2-((6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-(morpholin-3-yl)thiophen-2-yl)ethan-1-one;
102	2-((6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-(4-methylmorpholin-3-yl)thiophen-2-yl)ethan-1-one;
103	2-((5-fluoro-6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)ethan-1-one;
104	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((2-methyl-6-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
105	2-((6,7-dimethoxy-2-methylquinazolin-4-yl)thio)-1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)ethan-1-one;
106	2-((7-chloroquinolin-4-yl)thio)-1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)ethan-1-one;
107	2-((6,7-dimethoxyquinolin-4-yl)thio)-1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)ethan-1-one;
108	2-((6-chloro-7-fluoro-2-methylquinazolin-4-yl)thio)-1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)ethan-1-one;
109	2-((3-chloro-7-methyl-1,6-naphthyridin-5-yl)thio)-1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)ethan-1-one;
110	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((3-methoxy-7-methyl-1,6-naphthyridin-5-yl)thio)ethan-1-one;

111	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((6-methoxyquinolin-4-yl)thio)ethan-1-one;
112	1-(5-(hydroxy(1-methylpiperidin-4-yl)methyl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
113	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinolin-4-yl)thio)ethan-1-one;
114	2-((6-chloro-8-fluoro-2-methylquinazolin-4-yl)thio)-1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)ethan-1-one;
115	2-((6-chloroquinolin-4-yl)thio)-1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)ethan-1-one;
116	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((7-methoxyquinolin-4-yl)thio)ethan-1-one;
117	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((7-methylimidazo[1,2-a]pyrimidin-5-yl)thio)ethan-1-one;
118	2-((6-ethoxy-2-methylquinazolin-4-yl)thio)-1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)ethan-1-one;
119	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((2-methyl-1,8-naphthyridin-4-yl)thio)ethan-1-one;
120	1-(5-(3-hydroxy-1-methylpiperidin-3-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
121	4-(5-(2-((6-methoxy-2-methylquinazolin-4-yl)thio)acetyl)thiophen-2-yl)-1-methylpiperidine-4-carbonitrile;
122	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((2-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
123	1-(5-((3R,4S)-4-hydroxy-1,3-dimethylpiperidin-4-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one; and 1-(5-((3S,4R)-4-hydroxy-1,3-dimethylpiperidin-4-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
124	1-(5-(4-hydroxy-1-(2,2,2-trifluoroethyl)piperidin-4-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
125	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((2-methylquinazolin-4-yl)thio)ethan-1-one;
126 or 127	1-(5-((3R,4S)-3-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
126 or 127	1-(5-((3S,4R)-3-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
128	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((1-methyl-6-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)ethan-1-one;
129	1-(5-(3-hydroxyazetidin-3-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
130	1-(5-(3-hydroxy-1-methylazetidin-3-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
131	1-(5-(3-hydroxy-1-isopropylazetidin-3-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;

133	1-(5-(3-hydroxypyrrolidin-3-yl)thiophen-2-yl)-2-((6-methoxy-2-methyl-1,8-naphthyridin-4-yl)thio)ethan-1-one;
134	1-(2-(2,5-diazabicyclo[2.2.1]heptan-2-yl)thiazol-5-yl)-2-((2-methyl-6-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
135	1-(2-(5-isopropyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)thiazol-5-yl)-2-((2-methyl-6-(trifluoromethyl)quinazolin-4-yl)thio)ethan-1-one;
136	2-((6-chloro-7-fluoro-2-methylquinazolin-4-yl)thio)-1-(5-(3-hydroxyazetidin-3-yl)thiophen-2-yl)ethan-1-one;
137	2-((6-chloro-7-fluoro-2-methylquinazolin-4-yl)thio)-1-(5-(3-hydroxy-1-methylazetidin-3-yl)thiophen-2-yl)ethan-1-one;
138	2-((6-chloro-7-fluoro-2-methylquinazolin-4-yl)thio)-1-(5-(3-hydroxy-1-isopropylazetidin-3-yl)thiophen-2-yl)ethan-1-one;
139	1-(5-((1S,4S,5S)-5-hydroxy-2-methyl-2-azabicyclo[2.2.1]heptan-5-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one; and 1-(5-((1R,4R,5R)-5-hydroxy-2-methyl-2-azabicyclo[2.2.1]heptan-5-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
140	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((7-(trifluoromethyl)imidazo[1,2-a]pyrimidin-5-yl)thio)ethan-1-one;
141	1-(5-(3-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
142 or 143 or 149 or 150	1-(5-((S)-hydroxy((R)-4-methylmorpholin-2-yl)methyl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
142 or 143 or 149 or 150	1-(5-((R)-hydroxy((R)-4-methylmorpholin-2-yl)methyl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
144	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((6-methoxy-2-methylpyrido[3,4-d]pyrimidin-4-yl)thio)ethan-1-one;
145	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((6-methoxy-2-methyl-1,8-naphthyridin-4-yl)thio)ethan-1-one;
147	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((2-methyl-6-(trifluoromethyl)quinolin-4-yl)thio)ethan-1-one;
148	1-(5-(hydroxy(tetrahydro-1H-pyrrolizin-7a(5H)-yl)methyl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
142 or 143 or 149 or 150	1-(5-((R)-hydroxy((S)-4-methylmorpholin-2-yl)methyl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
142 or 143 or 149 or 150	1-(5-((S)-hydroxy((S)-4-methylmorpholin-2-yl)methyl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;

151	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((6-methoxy-2-methyl-1,5-naphthyridin-4-yl)thio)ethan-1-one;
152	1-(5-(1-hydroxy-2-morpholinoethyl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
153	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((7-methyl-3-(trifluoromethyl)-1,6-naphthyridin-5-yl)thio)ethan-1-one;
154	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((2-methyl-6-(trifluoromethyl)-1,8-naphthyridin-4-yl)thio)ethan-1-one;
155	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((2-methyl-6-(trifluoromethyl)-2H-pyrazolo[3,4-d]pyrimidin-4-yl)thio)ethan-1-one;
156	2-((6-fluoro-2-methylpyrido[2,3-d]pyrimidin-4-yl)thio)-1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)ethan-1-one;
157 or 158	(R)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-(morpholin-2-yl)thiophen-2-yl)ethan-1-one;
157 or 158	(S)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-(morpholin-2-yl)thiophen-2-yl)ethan-1-one;
159 or 160	1-(5-((1R,4R,5R)-5-hydroxy-2-methyl-2-azabicyclo[2.2.1]heptan-5-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
159 or 160	1-(5-((1S,4S,5S)-5-hydroxy-2-methyl-2-azabicyclo[2.2.1]heptan-5-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
161	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((7-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
162	1-(5-((1S,4S,5S)-5-hydroxy-2-azabicyclo[2.2.1]heptan-5-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one; and 1-(5-((1R,4R,5R)-5-hydroxy-2-azabicyclo[2.2.1]heptan-5-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
163	1-(5-(3-hydroxyquinuclidin-3-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
164	1-(5-((1R,5S,7s)-7-hydroxy-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
165	1-(5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-1-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
166	1-(5-((1S,3S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
167 or 168	(S)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-(2-(trifluoromethyl)morpholin-2-yl)thiophen-2-yl)ethan-1-one;
167 or 168	(R)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-(2-(trifluoromethyl)morpholin-2-yl)thiophen-2-yl)ethan-1-one;

169 or 170	(S)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-(2-methylmorpholin-2-yl)thiophen-2-yl)ethan-1-one;
169 or 170	(R)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-(2-methylmorpholin-2-yl)thiophen-2-yl)ethan-1-one;
171 or 172	(S)-1-(5-(6,6-difluoro-1,4-oxazepan-2-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
171 or 172	(R)-1-(5-(6,6-difluoro-1,4-oxazepan-2-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
173	1-(5-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-1-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
174	2-((6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-((1S,4S)-5-methyl-2-oxa-5-azabicyclo[2.2.1]heptan-1-yl)thiophen-2-yl)ethan-1-one;
175	1-(5-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-1-yl)thiophen-2-yl)-2-((5-fluoro-6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
176	2-((5-fluoro-6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-((1S,4S)-5-methyl-2-oxa-5-azabicyclo[2.2.1]heptan-1-yl)thiophen-2-yl)ethan-1-one;
177	1-(5-((1R,3R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
178	2-((6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-((1R,4R)-5-methyl-2-oxa-5-azabicyclo[2.2.1]heptan-1-yl)thiophen-2-yl)ethan-1-one;
179	1-(5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-1-yl)thiophen-2-yl)-2-((5-fluoro-6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
180	1-(5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-1-yl)thiophen-2-yl)-2-((6-(difluoromethoxy)-2-methylquinazolin-4-yl)thio)ethan-1-one;
181	2-((6-(difluoromethoxy)-2-methylquinazolin-4-yl)thio)-1-(5-((1R,4R)-5-methyl-2-oxa-5-azabicyclo[2.2.1]heptan-1-yl)thiophen-2-yl)ethan-1-one;
182	2-((5-fluoro-6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-((1R,4R)-5-methyl-2-oxa-5-azabicyclo[2.2.1]heptan-1-yl)thiophen-2-yl)ethan-1-one;
183	1-(5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-1-yl)thiophen-2-yl)-2-((2-methyl-6-(trifluoromethoxy)quinazolin-4-yl)thio)ethan-1-one;
184	1-(5-((1R,4R)-5-methyl-2-oxa-5-azabicyclo[2.2.1]heptan-1-yl)thiophen-2-yl)-2-((2-methyl-6-(trifluoromethoxy)quinazolin-4-yl)thio)ethan-1-one;
185	1-(5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-1-yl)thiophen-2-yl)-2-((7-methyl-3-(trifluoromethyl)-1,6-naphthyridin-5-yl)thio)ethan-1-one;
186	1-(5-((1R,4R)-5-methyl-2-oxa-5-azabicyclo[2.2.1]heptan-1-yl)thiophen-2-yl)-2-((7-methyl-3-(trifluoromethyl)-1,6-naphthyridin-5-yl)thio)ethan-1-one;
187 or 188	1-(5-((1R,5S)-6-oxa-3-azabicyclo[3.2.1]octan-5-yl)thiophen-2-yl)-2-((5-fluoro-6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;

187 or 188	1-(5-((1S,5R)-6-oxa-3-azabicyclo[3.2.1]octan-5-yl)thiophen-2-yl)-2-((5-fluoro-6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
189 or 190	2-((5-fluoro-6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-((1R,5S)-3-methyl-6-oxa-3-azabicyclo[3.2.1]octan-5-yl)thiophen-2-yl)ethan-1-one; and
189 or 190	2-((5-fluoro-6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-((1S,5R)-3-methyl-6-oxa-3-azabicyclo[3.2.1]octan-5-yl)thiophen-2-yl)ethan-1-one

or a pharmaceutically acceptable salt and/or solvate of any one thereof.


15. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to claim 14, wherein said compound is selected from

72	1-(5-(4-hydroxy-1-methylpiperidin-4-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
95	2-((6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-(morpholin-2-yl)thiophen-2-yl)ethan-1-one;
165	1-(5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-1-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
173	1-(5-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-1-yl)thiophen-2-yl)-2-((6-methoxy-2-methylquinazolin-4-yl)thio)ethan-1-one;
174	2-((6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-((1S,4S)-5-methyl-2-oxa-5-azabicyclo[2.2.1]heptan-1-yl)thiophen-2-yl)ethan-1-one; and
178	2-((6-methoxy-2-methylquinazolin-4-yl)thio)-1-(5-((1R,4R)-5-methyl-2-oxa-5-azabicyclo[2.2.1]heptan-1-yl)thiophen-2-yl)ethan-1-one;

or a pharmaceutically acceptable salt and/or solvate of any one thereof.

16. **A pharmaceutical composition** comprising the compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims **1** to **15** and at least one pharmaceutically acceptable carrier.

17. A compound for use as a medicament, wherein said compound is a compound of formula (I)



(I)

or a pharmaceutically acceptable salt and/or solvate thereof;

wherein

Y^1, **Y^2** and **L** are independently as defined in claim **1**;

$Z^{1'}$ is selected from -N**$R^{23'}R^{24'}$** and a -(C_3-C_7) heterocycloalkyl comprising at least one nitrogen atom;

wherein

each nitrogen atom of said (C_3-C_7) heterocycloalkyl in **$Z^{1'}$** is optionally substituted with at least one group selected from -(C_1-C_6) alkyl, -(C_3-C_7) cycloalkyl,-(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl, heteroaryl, -(C_1-C_6) alkylene-O-(C_1-C_6) alkyl, -(C_1-C_6) alkylene-(C_3-C_7) heterocycloalkyl, -(C_1-C_6) alkylene-aryl, -(C_1-C_6) alkylene-heteroaryl, and-(C_1-C_6) alkylene-O-(C_3-C_7) cycloalkyl;

each carbon atom of said (C_3-C_7) heterocycloalkyl in **$Z^{1'}$** is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, -(C_1-C_6) alkyl, -(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl, heteroaryl, -(C_1-C_6) alkylene-O-(C_1-C_6) alkyl, -(C_1-C_6) alkylene-O-(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) heterocycloalkyl, -(C_1-C_6) alkylene-aryl, -(C_1-C_6) alkylene-heteroaryl, -O-(C_1-C_6) alkyl, and -O-(C_3-C_7) cycloalkyl;

wherein each of said -(C_1-C_6) alkyl, -(C_1-C_6) alkylene -(C_3-C_7) cycloalkyl or -(C_3-C_7) heterocycloalkyl in **$Z^{1'}$** is optionally substituted with at least one halogen; and

wherein each of said aryl or heteroaryl in **$Z^{1'}$** is optionally substituted with at least one group selected from halogen, CN, -(C_1-C_6) alkyl, -O-(C_1-C_6) alkyl, and O-(C_3-C_7) cycloalkyl; and


$R^{23'}$ and **$R^{24'}$** are each independently selected from hydrogen, -(C_1-C_6) alkyl, -(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl, heteroaryl, -(C_1-C_6) alkylene-(C_3-C_7) heterocycloalkyl, -(C_1-C_6) alkylene-heteroaryl, and -(C_1-C_6) alkylene-aryl;

wherein

each of said -(C_1-C_6) alkyl, -(C_1-C_6) alkylene, -(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl in **$R^{23'}$** or **$R^{24'}$** is optionally substituted with at least one group selected from halogen, cyano, hydroxy, -O-(C_1-C_6) alkyl, -NH-(C_1-C_6) alkyl, and -N-((C_1-C_6) alkyl)$_2$; and
each of said aryl or heteroaryl in **$R^{23'}$** or **$R^{24'}$** is optionally substituted with at least one group selected from halogen, cyano, hydroxy, -(C_1-C_6) alkyl, -O-(C_1-C_6) alkyl, -NH-(C_1-C_6) alkyl, and -N-((C_1-C_6) alkyl)$_2$.

18. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use according to claim **17** for use in the treatment and/or prevention of an HDAC6-associated disease.

19. Use of a compound in the manufacture of a medicament for the treatment and/or prevention of an HDAC6-associated disease, wherein said compound is a compound of formula (I)



(I)

or a pharmaceutically acceptable salt and/or solvate thereof;
wherein
Y^1, **Y^2** and **L** are independently as defined in claim **1**;
$Z^{1'}$ is selected from -N**$R^{23'}R^{24'}$** and a -(C_3-C_7) heterocycloalkyl comprising at least one nitrogen atom;
wherein
each nitrogen atom of said (C_3-C_7) heterocycloalkyl in **$Z^{1'}$** is optionally substituted with at least one group selected from -(C_1-C_6) alkyl, -(C_3-C_7) cycloalkyl,-(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl, heteroaryl, -(C_1-C_6) alkylene-O-(C_1-C_6) alkyl, -(C_1-C_6) alkylene-(C_3-C_7) heterocycloalkyl, -(C_1-C_6) alkylene-aryl, -(C_1-C_6) alkylene-heteroaryl, and-(C_1-C_6) alkylene-O-(C_3-C_7) cycloalkyl;

each carbon atom of said (C_3-C_7) heterocycloalkyl in **$Z^{1'}$** is optionally substituted with at least one group selected from halogen, cyano, hydroxy, oxo, -(C_1-C_6) alkyl, -(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl, heteroaryl, -(C_1-C_6) alkylene-O-(C_1-C_6) alkyl, -(C_1-C_6) alkylene-O-(C_3-C_7) cycloalkyl,
-(C_1-C_6) alkylene-(C_3-C_7) heterocycloalkyl, -(C_1-C_6) alkylene-aryl, -(C_1-C_6) alkylene-heteroaryl, -O-(C_1-C_6) alkyl, and -O-(C_3-C_7) cycloalkyl;
wherein each of said -(C_1-C_6) alkyl, -(C_1-C_6) alkylene -(C_3-C_7) cycloalkyl or -(C_3-C_7) heterocycloalkyl in **$Z^{1'}$** is optionally substituted with at least one halogen; and
wherein each of said aryl or heteroaryl in **$Z^{1'}$** is optionally substituted with at least one group selected from halogen, CN, -(C_1-C_6) alkyl, -O-(C_1-C_6) alkyl, and O-(C_3-C_7) cycloalkyl; and
$R^{23'}$ and **$R^{24'}$** are each independently selected from hydrogen, -(C_1-C_6) alkyl, -(C_3-C_7) cycloalkyl, -(C_1-C_6) alkylene-(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl, aryl, heteroaryl, -(C_1-C_6) alkylene-(C_3-C_7) heterocycloalkyl, -(C_1-C_6) alkylene-heteroaryl, and -(C_1-C_6) alkylene-aryl;
wherein
each of said -(C_1-C_6) alkyl, -(C_1-C_6) alkylene, -(C_3-C_7) cycloalkyl, -(C_3-C_7) heterocycloalkyl in **$R^{23'}$** or **$R^{24'}$** is optionally substituted with at least one group selected from halogen, cyano, hydroxy, -O-(C_1-C_6) alkyl, -NH-(C_1-C_6) alkyl, and -N-((C_1-C_6) alkyl)$_2$; and
each of said aryl or heteroaryl in **$R^{23'}$** or **$R^{24'}$** is optionally substituted with at least one group selected from halogen, cyano, hydroxy, -(C_1-C_6) alkyl, -O-(C_1-C_6) alkyl, -NH-(C_1-C_6) alkyl, and -N-((C_1-C_6) alkyl)$_2$.

20. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use according to claim **17** or claim **18**, or the use according to claim **19**, wherein said HDAC6-associated disease is selected from the group consisting of inflammatory diseases, autoimmune diseases, proliferative diseases, neurodegenerative diseases, pains,

neuropathies, psychiatric diseases, neurodevelopmental disorders, sleep disorders, cardiovascular diseases, and metabolic or hormonal disorders.

21. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use according to claim **17** or claim **18**, or the use according to claim **19**, wherein said HDAC6-associated disease is a neuropathy selected from the group consisting of Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), Charcot-Marie-Tooth disease, hereditary sensory and autonomic neuropathy, familial amyloidotic polyneuropathy, chemotherapy-induced peripheral neuropathy (CIPN) using chemotherapeutic anticancer agents, diabetic peripheral neuropathy (DPN), neuralgia, pain and neuropathic pain; a neurodegenerative disease selected from the group consisting of Alzheimer's disease, dementia of Alzheimer type, Alzheimer-type senile dementia, Parkinson's disease, muscular dystrophy, Parkinson's disease associated with dementia, senile dementia, age-related cognition memory disorders, Huntington's disease, multi-infarct dementia, frontotemporal lobar degeneration, frontotemporal dementia, Pick's disease, Parkinson's type dementia, Niemann-Pick syndrome, Down's disease, vascular dementia, postencephalitic parkinsonism, Lewy body dementia, Rubinstein-Taybi syndrome, HIV dementia, amyotrophic lateral sclerosis (ALS), motor neurogenesis disease (MND) and Creutzfeldt; or a neurodevelopmental disorder selected from the group consisting of Tourette syndrome, autism, autistic spectrum syndrome, fragile X syndrome, Rett syndrome, and attention deficit hyperactivity disorder (ADHD).

22. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use according to claim **17** or claim **18**, or the use according to claim **19**, wherein said HDAC6-associated disease is a cardiovascular disease selected from the group consisting of heart failure, cardiomyopathy and myocarditis; a metabolic or hormonal disorder selected from the group consisting of obesity, diabetes, acromegaly, infertility and metabolic syndrome; or an inflammatory disease is selected from the group consisting of acute pancreatitis, chronic pancreatitis, asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, inflammatory bone disease,

inflammatory pulmonary disease, inflammatory bowel disease, celiac disease, hepatitis, systemic inflammatory response syndrome (SIRS), postoperative or posttraumatic inflammation, pneumonia, nephritis, meningitis, cystitis, pharyngolaryngitis, gastric mucosal injury, spondylitis, arthritis, dermatitis, chronic pneumonia, bronchitis, pulmonary infarction, silicosis, pulmonary sarcoidosis, diabetic nephropathy, uveitis, suppurative hidradenitis, cerebrospinal meningitis, inflammatory bowel disease, ulcerative colitis and Crohn's disease.

23. A process for manufacturing the compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims **1** to **15**, wherein said process comprises the following steps: (i) reacting an amine-containing alkyl chain or heterocycloalkyl with a halo-heterocycle; then (ii) reacting a heterocycle or halo-heterocycle with first an acetylating reagent, and, where appropriate, subsequently a halogenating reagent, to form a halo-ketone; then (iii) reacting a halo-ketone with a thiol and, where appropriate, (iv) removing of at least one protective group.